14 results about "Cardiac myosin" patented technology

The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being a cardiac Troponin, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), comparing the amounts of the biomarkers to references for said biomarkers and / or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and / or the calculation. The invention also relates to the use of a first biomarker being a cardiac Troponin and a second biomarker selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.

Provided herein are improved assays, methods, and systems for determining the amount, concentration, or level of cardiac myosin binding protein C ("cMyC") in a biological sample obtained from a subject. The improved assays, methods, and systems can generate a result (e.g., the amount or level of cMyC) in less than about 1 hour and are highly specific and sensitive.

Methods for treating non-obstructive hypertrophic cardiomyopathy or mid-ventricular obstructive (MVO) hypertrophic cardiomyopathy are described herein. The treatment methods include administration of a myocardial myosin inhibitor (CK-274 or CK-3773274, also referred to as aficamten), and may include adjusting the daily dose administered based on components of an echocardiogram. The daily dose may be increased, maintained, decreased, or terminated based on the echocardiogram. In some embodiments, the dose is adjusted once during the course of treatment. In some embodiments, the dose is adjusted two or more times during the course of treatment. The daily dose may be administered to the patient in a constant amount for about two weeks before the amount of the daily dose is adjusted.

Methods for treating obstructive hypertrophic cardiomyopathy are described herein. The treatment methods include the administration of a cardiac myosin inhibitor (CK-3773274, also referred to as CK-274 or aficamten) and may include titrating an administrated daily dose based on one or more components of an echocardiogram. The daily dose may be increased, maintained, decreased, or terminated, based on the echocardiogram.

The utility model discloses a multi-index joint detection kit for heart failure risk assessment, which comprises a shell and a detection card, and the detection card comprises a bottom plate, a sample pad, a combination pad, a detection pad and a sample absorption pad; the multiple indexes comprise three indexes including peptin, cardiac myosin binding protein C and adrenal medullary middle segment peptide; an antibody coating marked by a fluorescent substance is arranged on the combination pad, and an antibody in the antibody coating is a specific detection antibody aiming at three indexes; three parallel and spaced detection lines and a quality control line are arranged on the detection pad, the three detection lines are respectively coated with specific capture antibodies in one-to-one correspondence with three indexes of peptin, cardiac myosin binding protein C and adrenal medullary midsection peptide, and the quality control line is coated with haptens or antibodies capable of being combined with the specific detection antibodies. According to the utility model, three indexes are jointly detected, the detection sensitivity is high, the detection range is wide, and the accuracy and the specificity of early risk assessment of heart failure can be improved.

Provided herein are gene therapy compositions and methods for treating reduced levels of functional cardiac myosin binding protein C in subjects with hypertrophic cardiomyopathy.

The present disclosure relates to co-crystal of Aficamten and tartaric acid, and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the co-crystal for preparing cardiac myosin inhibitor and drugs for treating hypertrophic cardiomyopathy.

Provided herein are gene therapy compositions and methods of treating reduced levels of functional cardiac myosin binding protein C in a subject having hypertrophic cardiomyopathy.

Methods for treating obstructive hypertrophic cardiomyopathy are described herein. The treatment methods include the administration of a cardiac myosin inhibitor (CK-3773274, also referred to as CK-274 or aficamten) and may include titrating an administrated daily dose based on one or more components of an echocardiogram. The daily dose may be increased, maintained, decreased, or terminated, based on the echocardiogram.

The invention relates to a co-crystal of Aficamten and tartaric acid, a preparation method of the co-crystal, a pharmaceutical composition containing the co-crystal, and application of the co-crystal in preparation of a cardiac myosin inhibitor drug and a drug for treating hypertrophic cardiomyopathy.

The invention discloses a cardiac myosin binding protein C specific antibody composition and a kit thereof. The composition comprises a first antibody and a second antibody, the composition specifically recognizes cardiac myosin binding protein C, and the amino acid sequence of a recognition site is shown as SEQ ID No.5. The kit comprises a magnetic microsphere coupled with a first antibody, a fluorescent microsphere coupled with a second antibody, a calibrator and a diluent. The cardiac myosin binding protein C antibody provided by the invention has good specificity and high affinity with cardiac myosin binding protein C, avoids crossing with skeletal muscle myosin, and can be used for preparing a fluorescence immunoassay product for detecting cardiac myosin binding protein C. The cardiac myosin binding protein C detection kit provided by the invention has the advantages of simple equipment, simplicity in operation, easiness in popularization and the like.

Provided herein is a myosin binding protein C detection kit, comprising: 1) a magnetic bead coupled with a first antibody, and 2) a second antibody coupled with an acridinium ester, the first antibody and the second antibody both being human myosin binding protein C antibodies, but binding to different antigenic epitopes. By means of a double antibody sandwich method and the chemiluminescence characteristics of the acridinium ester, the myosin binding protein C detection kit detects the content of myosin binding protein C in serum with high sensitivity.

The present invention discloses a cardiac myosin binding protein C-specific antibody composition and a kit thereof, wherein the composition comprises a first antibody and a second antibody, and the composition specifically recognizes cardiac myosin binding protein C, and the amino acid sequence of the recognition site is shown in SEQ ID No. 5. The kit comprises magnetic microspheres coupled with the first antibody, fluorescent microspheres coupled with the second antibody, a calibrator, and a diluent. The cardiac myosin binding protein C antibody provided by the present invention has good specificity and high affinity with cardiac myosin binding protein C, avoids cross-talk with skeletal muscle myosin, and can be used to prepare fluorescent immunoassay products for detecting cardiac myosin binding protein C. The cardiac myosin binding protein C detection kit provided by the present invention has the advantages of simple equipment, simple operation, and easy promotion.

This invention discloses a monoclonal paired antibody against cardiac myosin-binding protein C and its application. The specific antibody comprises a first antibody and / or a second antibody; the first antibody and the second antibody bind to different epitopes of cardiac myosin-binding protein C, and the similarity between the heavy chain CDR3 sequence of the first antibody and the heavy chain CDR3 sequence of the second antibody is <70%, and the similarity between the light chain CDR3 sequence of the first antibody and the light chain CDR3 sequence of the second antibody is <70%. The monoclonal paired antibody against cardiac myosin-binding protein C of this invention exhibits high specificity and high affinity, with a cross-reactivity rate of <1% with skeletal muscle myosin-binding protein. The kit of this invention has a detection sensitivity ≤5 pg / mL and a detection time of only 10-15 min, making it suitable for the ultra-early diagnosis of acute myocardial infarction.